Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

By V. Nell, K. Machold, G. Eberl, T. Stamm, M. Uffmann, J. Smolen. Rheumatology, 2004

807 citations recorded by the source corpus.

Citations in the corpus

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, neutral): “are now well established. Furthermore, treatment strategies have changed during this period, initially by calling for early referral and early institution of DMARD treatment on the basis of respective evidence of clinical efficacy,”
Treating rheumatoid arthritis to target: recommendations of an international task force (2010, neutral): “The paradigmatic changes mentioned above are related to several factors. First, less joint damage and better physical function have been unequivocally shown to be a consequence of the early institution of disease-modifying antirheumatic drugs (DMARDs) when compared with their delayed start.”